Assessment Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indicator: Together with chemotherapy, for the procedure of adult clients with domestically recurrent unresectable or metastatic triple-negative breast cancer who may have not been given prior chemotherapy for metastatic disease and whose tumours express programmed mobile Demise-ligand one (blended beneficial score ≥... https://georgese791eff5.vidublog.com/profile